21 April 2016 ANTEO DIAGNOSTICS PROGRESSES TO PCT ON BATTERY...

21 April 2016
ANTEO DIAGNOSTICS PROGRESSES TO PCT ON BATTERY COMPOSITION PATENT.
Highlights
 Patent progression sets out a broad range of use for Anteo nano-coatings
Anteo Diagnostics Limited (ASX: ADO) is pleased to announce that the PCT application “Composition” was filed 20 April, 2016, as foreshadowed following the filing of two new patents applications.
This, the first of three patent applications directed at the Energy sector, which are applicable to batteries, super-capacitors and similar products. The two recent applications are supportive of these Energy applications; and together the three patent applications cover other important industrial uses of Anteo’s coating technology.
“Nanomaterials used in life science research such as silicon and other metal oxide particles are the same or similar to particles used in other industries such as lithium- ion batteries The concept that a technology capability that is used to develop diagnostic and life science products can also be used for high performance batteries and other industrial coatings or composites in other markets is consequently a natural progression of our nanometre thin coatings.” said Dr Joe Maeji Chief Scientific Officer, Anteo Technologies.
Dr Maeji continued: “Our market investigation at the recent Tokyo Battery Expo early this year was highly encouraging and commercialisation is now the main topic. This PCT application covers coatings for both new anode and cathode materials; and our initial business focus will be silicon-based anodes. Silicon has over 10x times the theoretical energy storage density compared to current graphite based anodes but its use is complicated by the material swelling and shrinking during charge and discharge, resulting in fragmentation and destroying battery performance.
“Anteo coatings are “self-healing” coatings able to prevent fragmentation and silicon isn’t the only material having these problems. Similarly, there are also inherent stability problems of new cathode materials that can be resolved by Anteo coatings. The PCT filing is an important milestone in the commercialisation activities in the industrial area and we will be interacting with potential partners over the next 6 to 9 months ” said Dr Maeji.
About Anteo
Anteo Diagnostics Limited (ASX: ADO) is a global technology company, developing and commercialising products for sale into the life sciences, in-vitro diagnostics, point of care, medical devices bioseparations and energy markets.
The Anteo group owns a patented nanoglue technology, which is used by healthcare customers for incorporation into their existing tests and tests under development, to consistently enable laboratory test results that can either be delivered faster, cheaper, or with greater specificity or sensitivity than incumbent tests.
This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction with the Company’s target markets, due to its ability to revolutionise the way scientists work.
While Anteo is largely focused on the healthcare markets, the nanoglue technology also has potential for use in other areas, such as batteries. Early stage research is being progressed into the viability of this battery product.
For more information, please visit www.anteodx.com